The modulation of cell surface and activation marker expression by dalazatide treatment suggests that the 60 mcg dalazatide treatment dose engaged the Kv1.3 target on CD2+ memory T cells as well as CD2+CLA+ memory T cells homing to the skin of psoriasis patients. The gene discussed is KCNA3; the disease is psoriasis.